title: Effect of preexisting statin use on expression of C-reactive protein, adhesion molecules, interleukin-6, and antioxidized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting.
abstract: BACKGROUND
  Statins are believed to reduce coronary heart disease by mechanisms in addition to their well-known cholesterol lowering effect.
  
  
  OBJECTIVE
  We studied the effect of statins on expression of C-reactive protein (CRP), interleukin-6 (IL-6), adhesion molecules, and antioxidized low-density lipoprotein antibody (anti-oxLDL Ab) in patients with unstable angina (Braunwald class IIb or IIIb) undergoing coronary stenting.
  
  
  METHODS
  Consecutive 50 patients with unstable angina were included in the study. We classified the study subjects as patients using statins (Group A, n=20, men 10, mean age 62 years) and patients not using statins (Group B, n=30, men 15, mean age 60 years).
  
  
  RESULTS
  Baseline levels of inflammatory markers were similar in the two groups. However, 24 h after coronary stenting, serum levels of CRP (2.00 vs. 4.63 mg/l, p < 0.05), intercellular adhesion molecule-1 (ICAM-1) (217 vs. 261 ng/ml, p < 0.01), and anti-oxLDL Ab (8.97 vs. 12.96 U/ml, p < 0.05) were significantly higher in Group B than in Group A. Furthermore, 72 h after coronary stenting, serum levels of CRP (3.00 vs. 5.50 mg/l, p < 0.01) and ICAM-1 (222 vs. 277 ng/ml, p < 0.05) were significantly higher in Group B than in Group A.
  
  
  CONCLUSIONS
  Preexisting statin therapy plays a role in reducing the serum levels of CRP, ICAM-1, and anti-oxLDL Ab after coronary stenting in patients with unstable angina. These data support an anti-inflammatory or plaque-stabilizing effect of statin therapy.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Kang-Dong Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea. ycdoo97@yahoo.co.kr
authors.forename: Young-Cheoul
authors.initials: YC
authors.lastname: Doo
authors.forename: Sang-Jin
authors.initials: SJ
authors.lastname: Han
authors.forename: Sung-Woo
authors.initials: SW
authors.lastname: Han
authors.forename: Woo-Jung
authors.initials: WJ
authors.lastname: Park
authors.forename: Seung-Hyuk
authors.initials: SH
authors.lastname: Choi
authors.forename: Goo-Yeong
authors.initials: GY
authors.lastname: Cho
authors.forename: Kyung-Soon
authors.initials: KS
authors.lastname: Hong
authors.forename: Kyoo-Rok
authors.initials: KR
authors.lastname: Han
authors.forename: Nam-Ho
authors.initials: NH
authors.lastname: Lee
authors.forename: Dong-Jin
authors.initials: DJ
authors.lastname: Oh
authors.forename: Kyu-Hyung
authors.initials: KH
authors.lastname: Ryu
authors.forename: Chong-Yun
authors.initials: CY
authors.lastname: Rim
authors.forename: Kwang-Hahk
authors.initials: KH
authors.lastname: Lee
authors.forename: Yung
authors.initials: Y
authors.lastname: Lee
mesh_terms: D000789:Angina, Unstable / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis / Q000187:drug effects; D016009:Chi-Square Distribution; D003331:Coronary Vessels / Q000601:surgery; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood / Q000187:drug effects; D015850:Interleukin-6 / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D015607:Stents; D013997:Time Factors
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015850:Interleukin-6; D008077:Lipoproteins, LDL; C019455:low density lipoprotein inhibitor; D018799:Intercellular Adhesion Molecule-1; D002097:C-Reactive Protein